BACKGROUND: Refractory anemia with excess blasts subtype 1 (RAEB-1) is a subgroup of myelodysplastic syndrome. It represents a heterogeneous group of oncohematological bone marrow diseases, which occur particularly in elderly patients. The aim of this proteomic study was to search for plasma protein alterations in RAEB-1 patients. RESULTS: A total of 24 plasma samples were depleted of fourteen high-abundant plasma proteins, analyzed with 2D SDS-PAGE, compared, and statistically processed with Progenesis SameSpots software. Proteins were identified by nanoLC-MS/MS. Retinol-binding protein 4 and leucine-rich alpha-2-glycoprotein were relatively quantified using mass spectrometry. 56 significantly differing spots were found; and in 52 spots 50 different proteins were successfully identified. Several plasma proteins that changed either in their level or modification have been described herein. The plasma level of retinol-binding protein 4 was decreased, while leucine-rich alpha-2-glycoprotein was modified in RAEB-1 patients. Changes in the inter-alpha-trypsin inhibitor heavy chain H4, altered protein fragmentation, or fragments modifications were observed. CONCLUSIONS: This study describes proteins, which change quantitatively or qualitatively in the plasma of RAEB-1 patients. It is the first report on qualitative changes in the leucine-rich alpha-2-glycoprotein in the RAEB-1 subgroup of myelodysplastic syndrome. Described changes in the composition or modification of inter-alpha-trypsin inhibitor heavy chain H4 fragments in RAEB-1 are in agreement with those changes observed in previous study of refractory cytopenia with multilineage dysplasia, and thus H4 fragments could be a marker specific for myelodysplastic syndrome.

Institute of Hematology and Blood Transfusion U Nemocnice 1 128 20 Prague 2 Czech Republic

Zobrazit více v PubMed

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302. doi: 10.1182/blood-2002-04-1199. PubMed DOI

Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet. 2011;19:313–319. doi: 10.1038/ejhg.2010.209. PubMed DOI PMC

Zhong LY, Liu TH, Li YQ, Geng SX, Lu ZS, Weng JY, Wu SJ, Luo CW, Du X. Serum proteomics in patients with RAEB myelodysplastic syndromes. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:1799–1801. PubMed

Rodriguez-Emmenegger C, Brynda E, Riedel T, Houska M, Subr V, Alles AB, Hasan E, Gautrot JE, Huck WT. Polymer brushes showing non-fouling in blood plasma challenge the currently accepted design of protein resistant surfaces. Macromol Rapid Commun. 2011;32:952–957. doi: 10.1002/marc.201100189. PubMed DOI

Rodriguez Emmenegger C, Brynda E, Riedel T, Sedlakova Z, Houska M, Alles AB. Interaction of blood plasma with antifouling surfaces. Langmuir. 2009;25:6328–6333. doi: 10.1021/la900083s. PubMed DOI

Riedel T, Brynda E, Dyr JE, Houska M. Controlled preparation of thin fibrin films immobilized at solid surfaces. J Biomed Mater Res A. 2009;88:437–447. PubMed

Májek P, Reicheltová Z, Suttnar J, Malý M, Oravec M, Pečánková K, Dyr JE. Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. J Transl Med. 2011;9:84. doi: 10.1186/1479-5876-9-84. PubMed DOI PMC

Májek P, Reicheltová Z, Stikarová J, Suttnar J, Sobotková A, Dyr JE. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci. 2010;8:56. PubMed PMC

Riedel T, Suttnar J, Brynda E, Houska M, Medved L, Dyr JE. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood. 2011;117:1700–1706. doi: 10.1182/blood-2010-08-300301. PubMed DOI PMC

Kay R, Barton C, Ratcliffe L, Matharoo-Ball B, Brown P, Roberts J, Teale P, Creaser C. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom. 2008;22:3255–3260. doi: 10.1002/rcm.3729. PubMed DOI

Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, Blazevich AJ, Godfrey RJ, Goldspink G, Rees R, Ball GR, Cowan DA, Harridge SD, Roberts J, Teale P, Creaser CS. High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom. 2009;23:3173–3182. doi: 10.1002/rcm.4237. PubMed DOI

Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222. PubMed PMC

Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049–2054. doi: 10.1038/sj.leu.2400844. PubMed DOI

Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol. 1997;99:625–631. doi: 10.1046/j.1365-2141.1997.4373247.x. PubMed DOI

Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427–1434. doi: 10.1182/blood.V97.5.1427. PubMed DOI

Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci. 2010;8:58. doi: 10.1186/1477-5956-8-58. PubMed DOI PMC

Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG. Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q) Leukemia. 2010;24:1875–1884. doi: 10.1038/leu.2010.182. PubMed DOI

Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271–284. PubMed PMC

Mohamed E, Abdul-Rahman PS, Doustjalali SR, Chen Y, Lim BK, Omar SZ, Bustam AZ, Singh VA, Mohd-Taib NA, Yip CH, Hashim OH. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis. 2008;29:2645–2650. doi: 10.1002/elps.200700828. PubMed DOI

Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882–5890. doi: 10.1158/0008-5472.CAN-04-0746. PubMed DOI

Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer. 2005;115:783–789. doi: 10.1002/ijc.20928. PubMed DOI

Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE. Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci. 2011;9:64. doi: 10.1186/1477-5956-9-64. PubMed DOI PMC

Haupt H, Baudner S. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum. Hoppe Seylers Z Physiol Chem. 1977;358:639–646. doi: 10.1515/bchm2.1977.358.1.639. PubMed DOI

Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun. 2009;382:776–779. doi: 10.1016/j.bbrc.2009.03.104. PubMed DOI PMC

O'Donnell LC, Druhan LJ, Avalos BR. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol. 2002;72:478–485. PubMed

Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S, Hirohashi S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics. 2006;6:3938–3948. doi: 10.1002/pmic.200500883. PubMed DOI

Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Yamada T, Kato H, Nishimura T, Todo S, Hirohashi S. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:257–267. doi: 10.1016/j.jchromb.2007.01.029. PubMed DOI PMC

Andersen JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Vogel RI, Skubitz AP. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res. 2010;3:21. doi: 10.1186/1757-2215-3-21. PubMed DOI PMC

Liu T, Qian WJ, Gritsenko MA, Camp DG, Monroe ME, Moore RJ, Smith RD. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005;4:2070–2080. doi: 10.1021/pr0502065. PubMed DOI PMC

Ramachandran P, Boontheung P, Xie Y, Sondej M, Wong DT, Loo JA. Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. J Proteome Res. 2006;5:1493–1503. doi: 10.1021/pr050492k. PubMed DOI

Zanotti G, Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm. 2004;69:271–295. PubMed

Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007;92:2712–2719. doi: 10.1210/jc.2006-1249. PubMed DOI

Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92:1971–1974. doi: 10.1210/jc.2006-2712. PubMed DOI

Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Dückers H, Trautwein C, Tacke F. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care. 2010;14:R179. doi: 10.1186/cc9285. PubMed DOI PMC

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups

Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome

Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome